search icon

    Market Snapshot

    • S&P Futures

      3,819

    • Dow Futures

      30,822

    • Nasdaq Futures

      11,785

    blog search icon

    BioCryst Pharmaceuticals, Inc.

    (NASDAQ:BCRX)

    $11.23

    $0.09

    0.81%

    BioCryst Pharmaceuticals, Inc. Chart

    BCRX Stock Price Today

    BioCryst Pharmaceuticals, Inc. (BCRX) stock rallied over 0.81% intraday to trade at $11.23 a share on NASDAQ. The stock opened with a gain of 5.55% at $11.1 and touched an intraday high of $11.608, rising 0.81% against the last close of $11.14. The stock went to a low of $11.06 during the session.

    Stock Snapshot

    $11.14

    Prev. Close

    2.03 Billion

    Market Cap

    $11.06

    Day Low

    $11.1

    Open

    184.9 Million

    Number of Shares

    $11.608

    Day High

    -

    P/E ratio

    -1.07

    EPS (TTM)

    2.75

    Cash Flow per Share

    16.15

    Free Float in %

    -0.82

    Book Value

    2,523,197

    Volume

    BioCryst Pharmaceuticals, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-07-06$11.1$11.608$11.06$11.232,521,212
    2022-07-05$10.64$11.17$10.55$11.143,044,800
    2022-07-01$10.59$10.92$10.33$10.842,533,100
    2022-06-30$10.62$10.88$10.46$10.581,908,300
    2022-06-29$10.44$10.92$10.44$10.812,125,100
    2022-06-28$10.88$10.96$10.3$10.463,796,900
    2022-06-27$10.84$10.95$10.33$10.883,449,500
    2022-06-24$10.25$10.91$10.19$10.766,847,400
    2022-06-23$9.56$10.23$9.32$10.174,470,800
    2022-06-22$9.26$9.81$9.19$9.492,834,700

    Contact Details

    4505 Emperor Boulevard
    Suite 200
    Durham, NC 27703
    United States

    Webiste:BCRX

    919 859 1302

    Company Information

    Employees-

    Beta2.29

    Sales or Revenue157.17 Million

    5Y Sales Change42.90%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

    Frequently Asked Questions

    icon

    What is the current BioCryst Pharmaceuticals, Inc. (BCRX) stock price?

    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) stock price is $11.23 as of the last check on Wednesday, July 6. During the trading session, BCRX stock reached the peak price of $11.608 while $11.06 was the lowest point it dropped to.

    icon

    BCRX's industry and sector of operation?

    The NASDAQ listed BCRX is part of Biotechnology industry that operates in the broader Health Care sector. BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers novel, oral, and small-molecule medicines.

    icon

    Who are the executives of BCRX?

    Mr. John D. Bluth
    Sr. VP of Investor Relations & Corp. Communications
    Mr. Robert C. Stoner
    VP of HR
    Mr. Jon P. Stonehouse
    CEO, Pres & Exec. Director
    Mr. Anthony J. Doyle
    Sr. VP & CFO

    icon

    What is the BCRX stock price today?

    BCRX stock traded closed the last session at $11.23, which is $0.09 or 0.81% lower than its previous close of $11.14. BCRX's current trading price is 47.57% lower than its 52-week high of $19.99 where as its distance from 52-week low of 7.61% is -43.82%.

    icon

    How many employees does BCRX have?

    Number of BCRX employees currently stands at -. BCRX operates from 4505 Emperor Boulevard, Suite 200, Durham, NC 27703, United States.

    icon

    Link for BCRX official website?

    Official Webiste of $BCRX is: https://www.biocryst.com

    icon

    How do I contact BCRX?

    BCRX could be contacted at BCRX operates from 4505 Emperor Boulevard, Suite 200, Durham, NC 27703, United States, or at phone #919 859 1302 and can also be accessed through its website.

    icon

    How many shares of BCRX are traded daily?

    BCRX stock volume for the day was 2,523,197 shares while in the previous session number of BCRX shares traded was 2,521,212 . The average number of BCRX shares traded daily for last 3 months was 5 Million.

    icon

    How much did BCRX change today?

    The percentage change in BCRX stock occurred in the recent session was 0.81% while the dollar amount for the price change in BCRX stock was $0.09.

    icon

    What price range BCRX stock been trading in?

    In the recent session, the day high for BCRX stock was $11.608 while the low for BCRX stock touched on the day was $11.06.

    icon

    What is the market cap of BCRX currently?

    The market value of BCRX currently stands at 2.03 Billion with its latest stock price at $11.23 and 184.9 Million of its shares outstanding.